CBAY CymaBay Therapeutics Inc Stock Price Quote NASDAQ

The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank. Plus, CBAY info will be updated daily in your Zacks.com Portfolio Tracker – also free.

• Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC).
• CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs.
• Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year.
• We’d like to share more about how we work and what drives our day-to-day business.

This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.32% per year. These returns cover a period from January 1, 1988 through July 31, 2023.

CymaBay Therapeutics, Inc. (CBAY)

A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. Riley, BTIG Research, Cantor Fitzgerald, Guggenheim, HC Wainwright, Jonestrading, Raymond James, and UBS Group in the past 90 days.

The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

CBAY Overview

On a nine-point scale measuring itch symptoms, seladelpar recipients had an average reduction of 3.2 points compared with just 1.7 points in the placebo group. One quarter of patients reached normal enzyme levels, indicating liver damage had stopped. MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

The average twelve-month price prediction for CymaBay Therapeutics is $19.18 with a high price target of $33.00 and a low price target of $12.00. This press release contains forward-looking statements, including statements relating to CymaBay’s expectations regarding the timing of the closing of the public offering and anticipated use of proceeds. These statements are subject to significant risks and uncertainties and actual results could differ materially 3 types of unemployment from those projected. CymaBay cautions investors not to place undue reliance on the forward-looking statements contained in this press release. These risks and uncertainties include, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering. There can be no assurance that CymaBay will be able to complete the public offering on the anticipated terms, or at all.

They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. CymaBay Therapeutics, Inc. engages in the provision and development of access to therapies for patients with liver and other chronic diseases with high unmet medical needs. Its products pipeline includes Seladelpar, MBX-2982, CB-0406, and CB-001. CymaBay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $21.64, a 26.33% upside from current levels.

Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements. © 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.

CymaBay Therapeutics Inc.

CymaBay Therapeutics’ stock is owned by a variety of institutional and retail investors. Insiders that own company stock include Charles Mcwherter, Daniel Menold, Dennis D Kim, Paul T Quinlan and Sujal Shah. CymaBay Therapeutics saw a decline in short interest https://1investing.in/ in August. As of August 31st, there was short interest totaling 8,960,000 shares, a decline of 21.1% from the August 15th total of 11,350,000 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is presently 3.7 days.

The Motley Fool has no position in any of the stocks mentioned. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. We’d like to share more about how we work and what drives our day-to-day business. Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CBAY’s beta can be found in Trading Information at the top of this page.

Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug

CymaBay undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in CymaBay’s expectations. The company tested its drug in patients with primary biliary cholangitis, a chronic inflammatory disease that slowly destroys the liver. After a year, the company tested levels of enzymes related to liver damage. Almost 62% of patients who received CymaBay’s drug, dubbed seladelpar, saw lower enzyme levels, compared with 20% of placebo recipients. 12 Wall Street equities research analysts have issued «buy,» «hold,» and «sell» ratings for CymaBay Therapeutics in the last year.

Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.

Upgrade to MarketBeat All Access to add more stocks to your watchlist. One share of CBAY stock can currently be purchased for approximately $16.91. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services.

The S&P 500 is highly concentrated on the largest tech stocks. But there are other broad indexes with even heavier concentration to tech giants. If your trading operation lacks a cadre of PhDs to crunch data like Renaissance Technologies or D.E. Two abstracts focus on the unique mechanism of action of seladelpar; a third focuses on characterizing patient risk of PBC disease progression NEWARK, Calif. , June 7, 2023 /PRNewswire/ — CymaBay The…

Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CBAY in relation to earlier this year. Last month, Menold Daniel, the VP Finance of CBAY bought 15,500.00 shares for a total of $79,010.00.

Why Hooker Furnishings Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday’s Mid-Day Session

Bullishly for CBAY stock, there were no serious side effects related to seladelpar in the study. Side effects and patient discontinuations were consistent across patients who received the drug and those given the placebo, CymaBay said in a news release. But after six months of treatment, patients treated with seladelpar had a statistically significant reduction in itching vs. the placebo group.

• CymaBay Therapeutics saw a decline in short interest in August.
• A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return.
• But there are other broad indexes with even heavier concentration to tech giants.
• ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.

Monday morning, CymaBay announced that it had floated a $150 million issue of common stock and warrants. The clinical-stage biotech said it intends to grant the offering’s underwriting syndicate, led by BTIG, a 30-day option to purchase an additional 15% of the amount of shares in the issue. These shares include stock that undergirds the pre-funded warrants. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA. CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics.

Our Services

Dividend yield allows investors, particularly those interested in dividend-paying stocks,
to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price. The technique has proven to be very useful for finding positive surprises. Shares of CymaBay Therapeutics Inc. are down 77% in premarket trading after the biopharmaceutical company ended two studies and halted a third for its experimental drug seladelpar.

The announcement comes less than a week after CymaBay reported highly encouraging results from a phase 3 clinical trial of seladelpar. In the trial, the drug met all its primary and secondary endpoints. Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity.